BPC-157 (VEGF) (NO)
Endocrine symptoms that are due to benzodiazepines improve after withdrawal
Pregnant or breastfeeding individuals should avoid most research peptides
Howeverand this is a significant 'however'the scientific evidence to definitively prove that a localized IM injection of BPC 157 is superior to a SubQ injection for that same muscle injury is thin
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
the control only reached 35 % When they blocked VEGFR2 (with the selective inhibitor SU5416), all of these effects disappeared Why it matters: The last point is what holds the study together
